Skip to main content
SpringerLink
Log in

Advances in Imaging Brain Cancer

  • Chapter
  • First Online:
Book cover Emerging Concepts in Neuro-Oncology

Abstract

Imaging has been one of the most important methods of understanding brain tumors, but it is clear that conventional methods are too insensitive to understand tumor biology. New positron emission tomography (PET) and MR imaging biomarkers that can assess biological processes in tumors are being developed. These biomarkers can assess tumor metabolism, proliferation, cellularity, angiogenesis and vascularity, hypoxia, invasion, and gene and molecular marker expression have been developed. These biomarkers will provide the tools to better characterize and monitor brain tumors.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Bennett AH, Godlee RJ. Excision of a tumour from the brain. Lancet. 1884;124(3199):1090–1.

    Google Scholar 

  2. Sachs E. The problem of the glioblastomas. J Neurosurg. 1950;7:185–9.

    PubMed  CAS  Google Scholar 

  3. Todd IDH. Choice of volume in the X-ray treatment of supratentorial gliomas. Br J Radiol. 1963;36:645–9.

    PubMed  CAS  Google Scholar 

  4. Hochberg FH, Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology. 1980;30:907–11.

    PubMed  CAS  Google Scholar 

  5. Upadhyay N, Waldman AD. Conventional MRI ­evaluation of gliomas. Br J Radiol. 2011;84:S107–11.

    PubMed  Google Scholar 

  6. Lilja A, Bergstrom K, Spannare B, Olsson Y. Reliability of computed tomography in assessing histopathological features of malignant supratentorial gliomas. J Comput Assist Tomogr. 1981;5:625–36.

    PubMed  CAS  Google Scholar 

  7. Selker RG, Mendelow H, Walker M, Sheptak PE, Phillips JG. Pathological correlation of CT ring in recurrent, previously treated gliomas. Surg Neurol. 1982;17:251–4.

    PubMed  CAS  Google Scholar 

  8. Burger PC, Dubois PJ, Schold Jr SC, Smith Jr KR, Odom GL, Crafts DC, Giangaspero F. Computerized tomographic and pathologic studies of the untreated, quiescent, and recurrent glioblastoma multiforme. J Neurosurg. 1983;58:159–69.

    PubMed  CAS  Google Scholar 

  9. Kelly PJ, Daumas-Duport C, Kispert DB, Kall BA, Scheithauer BW, Illig JJ. Imaging-based stereotaxic serial biopsies in untreated intracranial glial ­neoplasms. J Neurosurg. 1987;66:865–74.

    PubMed  CAS  Google Scholar 

  10. Lunsford LD, Martinez AJ, Latchaw RE. Magnetic resonance imaging does not define tumor boundaries. Acta Radiol Suppl. 1986;369:154–6.

    PubMed  CAS  Google Scholar 

  11. Johnson PC, Hunt SJ, Drayer BP. Human cerebral gliomas: correlation of postmortem MR imaging and neuropathologic findings. Radiology. 1989;170:211–7.

    PubMed  CAS  Google Scholar 

  12. Watanabe M, Tanaka R, Takeda N. Magnetic resonance imaging and histopathology of cerebral gliomas. Neuroradiology. 1992;34:463–9.

    PubMed  CAS  Google Scholar 

  13. Brandsma D, Stalpers L, Taal W, Sminia P, van den Bent MJ. Clinical features, mechanisms, and ­management of pseudoprogression in malignant gliomas. Lancet Oncol. 2008;9:453–61.

    PubMed  Google Scholar 

  14. Brandes AA, Franceschi E, Tosoni A, Blatt V, Pession A, Tallini G, Bertorelle R, Bartolini S, Calbucci F, Andreoli A, Frezza G, Leonardi M, Spagnolli F, Ermani M. MGMT promoter methylation status Can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol. 2008;26:2192–7.

    PubMed  Google Scholar 

  15. Norden AD, Young GS, Setayesh K, Muzikansky A, Klufas R, Ross GL, Ciampa AS, Ebbeling LG, Levy B, Drappatz J, Kesari S, Wen PY. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology. 2008;70:779–87.

    PubMed  CAS  Google Scholar 

  16. Vos MJ, Uitdehaag BM, Barkhof F, Heimans JJ, Baayen HC, Boogerd W, Castelijns JA, Elkhuizen PH, Postma TJ. Interobserver variability in the radiological assessment of response to chemotherapy in glioma. Neurology. 2003;60:826–30.

    PubMed  CAS  Google Scholar 

  17. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, DeGroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28:1963–72.

    PubMed  Google Scholar 

  18. van den Bent MJ, Wefel JS, Schiff D, Taphoorn MJ, Jaeckle K, Junck L, Armstrong T, Choucair A, Waldman AD, Gorlia T, Chamberlain M, Baumert BG, Vogelbaum MA, Macdonald DR, Reardon DA, Wen PY, Chang SM, Jacobs AH. Response assessment in neuro-oncology (a report of the RANO group): assessment of outcome in trials of diffuse low-grade gliomas. Lancet Oncol. 2011;12:583–93.

    PubMed  Google Scholar 

  19. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK. WHO classification of tumours of the central nervous system. Lyon: IARC; 2007.

    Google Scholar 

  20. Warburg O. On the origin of cancer cells. Science. 1956;123:309–14.

    PubMed  CAS  Google Scholar 

  21. Goldman S, Levivier M, Pirotte B, Brucher JM, Wikler D, Damhaut P, Stanus E, Brotchi J, Hildebrand J. Regional glucose metabolism and histopathology of gliomas. A study based on positron emission ­tomography-guided stereotactic biopsy. Cancer. 1996;78:1098–106.

    PubMed  CAS  Google Scholar 

  22. Delbeke D, Meyerowitz C, Lapidus RL, Maciunas RJ, Jennings MT, Moots PL, Kessler RM. Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. Radiology. 1995;195:47–52.

    PubMed  CAS  Google Scholar 

  23. Levivier M, Goldman S, Pirotte B, Brucher JM, Baleriaux D, Luxen A, Hildebrand J, Brotchi J. Diagnostic yield of stereotactic brain biopsy guided by positron emission tomography with [18 F]fluorodeoxyglucose. J Neurosurg. 1995;82:445–52.

    PubMed  CAS  Google Scholar 

  24. Tralins KS, Douglas JG, Stelzer KJ, Mankoff DA, Silbergeld DL, Rostomily RC, Hummel S, Scharnhorst J, Krohn KA, Spence AM. Volumetric analysis of 18 F-FDG PET in glioblastoma multiforme: prognostic information and possible role in definition of target volumes in radiation dose escalation. J Nucl Med. 2002;43:1667–73.

    PubMed  Google Scholar 

  25. Di Chiro G, Oldfield E, Wright DC, De Michele D, Katz DA, Patronas NJ, Doppman JL, Larson SM, Ito M, Kufta CV. Cerebral necrosis after radiotherapy and/or intraarterial chemotherapy for brain tumors: PET and neuropathologic studies. AJR Am J Roentgenol. 1988;150:189–97.

    PubMed  Google Scholar 

  26. Chao ST, Suh JH, Raja S, Lee SY, Barnett G. The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery. Int J Cancer. 2001;96:191–7.

    PubMed  CAS  Google Scholar 

  27. Fulham MJ, Brunetti A, Aloj L, Raman R, Dwyer AJ, Di Chiro G. Decreased cerebral glucose metabolism in patients with brain tumors: an effect of corticosteroids. J Neurosurg. 1995;83:657–64.

    PubMed  CAS  Google Scholar 

  28. Roelcke U, von Ammon K, Hausmann O, Kaech DL, Vanloffeld W, Landolt H, Rem JA, Gratzl O, Radu EW, Leenders KL. Operated low grade astrocytomas: a long term PET study on the effect of radiotherapy. J Neurol Neurosurg Psychiatry. 1999;66:644–7.

    PubMed  CAS  Google Scholar 

  29. Isselbacher KJ. Sugar and amino acid transport by cells in culture—differences between normal and malignant cells. N Engl J Med. 1972;286:929–33.

    PubMed  CAS  Google Scholar 

  30. Roelcke U, Radu E, Ametamey S, Pellikka R, Steinbrich W, Leenders KL. Association of rubidium and C-methionine uptake in brain tumors measured by positron emission tomography. J Neurooncol. 1996;27:163–71.

    PubMed  CAS  Google Scholar 

  31. Kracht LW, Friese M, Herholz K, Schroeder R, Bauer B, Jacobs A, Heiss WD. Methyl-[11C]- l-methionine uptake as measured by positron emission tomography correlates to microvessel density in patients with glioma. Eur J Nucl Med Mol Imaging. 2003;30:868–73.

    PubMed  CAS  Google Scholar 

  32. Minn H, Clavo AC, Grenman R, Wahl RL. In vitro comparison of cell proliferation kinetics and uptake of tritiated fluorodeoxyglucose and L-methionine in squamous-cell carcinoma of the head and neck. J Nucl Med. 1995;36:252–8.

    PubMed  CAS  Google Scholar 

  33. Daemen BJ, Elsinga PH, Paans AM, Lemstra W, Konings AW, Vaalburg W. Suitability of rodent tumor models for experimental PET with L-[1–11C]tyrosine and 2-[18 F]fluoro-2-deoxy-D-glucose. Int J Rad Appl Instrum B. 1991;18:503–11.

    PubMed  CAS  Google Scholar 

  34. Ogawa T, Shishido F, Kanno I, Inugami A, Fujita H, Murakami M, Shimosegawa E, Ito H, Hatazawa J, Okudera T. Cerebral glioma: evaluation with methionine PET. Radiology. 1993;186:45–53.

    PubMed  CAS  Google Scholar 

  35. Derlon JM, Petit-Taboue MC, Chapon F, Beaudouin V, Noel MH, Creveuil C, Courtheoux P, Houtteville JP. The in vivo metabolic pattern of low-grade brain gliomas: a positron emission tomographic study using 18F-fluorodeoxyglucose and 11C-L-methylmethio­nine. Neurosurgery. 1997;40:276–87.

    PubMed  CAS  Google Scholar 

  36. De Witte O, Goldberg I, Wikler D, Rorive S, Damhaut P, Monclus M, Salmon I, Brotchi J, Goldman S. Positron emission tomography with injection of methionine as a prognostic factor in glioma. J Neurosurg. 2001;95:746–50.

    PubMed  Google Scholar 

  37. Herholz K, Holzer T, Bauer B, Schroder R, Voges J, Ernestus RI, Mendoza G, Weber-Luxenburger G, Lottgen J, Thiel A, Wienhard K, Heiss WD. 11C-methionine PET for differential diagnosis of low-grade gliomas. Neurology. 1998;50:1316–22.

    PubMed  CAS  Google Scholar 

  38. Thiel A, Pietrzyk U, Sturm V, Herholz K, Hovels M, Schroder R. Enhanced accuracy in differential diagnosis of radiation necrosis by positron emission tomography-magnetic resonance imaging coregistration: technical case report. Neurosurgery. 2000;46:232–4.

    PubMed  CAS  Google Scholar 

  39. Go KG, Keuter EJ, Kamman RL, Pruim J, Metzemaekers JD, Staal MJ, Paans AM, Vaalburg W. Contribution of magnetic resonance spectroscopic imaging and L-[1–11C]tyrosine positron emission tomography to localization of cerebral gliomas for biopsy. Neurosurgery. 1994;34:994–1002.

    PubMed  CAS  Google Scholar 

  40. Floeth FW, Pauleit D, Sabel M, Stoffels G, Reifenberger G, Riemenschneider MJ, Jansen P, Coenen HH, Steiger HJ, Langen KJ. Prognostic value of O-(2–18F-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma. J Nucl Med. 2007;48:519–27.

    PubMed  CAS  Google Scholar 

  41. Massager N, David P, Goldman S, Pirotte B, Wikler D, Salmon I, Nagy N, Brotchi J, Levivier M. Combined magnetic resonance imaging- and positron emission tomography-guided stereotactic biopsy in brainstem mass lesions: diagnostic yield in a series of 30 patients. J Neurosurg. 2000;93:951–7.

    PubMed  CAS  Google Scholar 

  42. Pirotte B, Goldman S, Salzberg S, Wikler D, David P, Vandesteene A, Van Bogaert P, Salmon I, Brotchi J, Levivier M. Combined positron emission tomography and magnetic resonance imaging for the planning of stereotactic brain biopsies in children: experience in 9 cases. Pediatr Neurosurg. 2003;38:146–55.

    PubMed  Google Scholar 

  43. Pirotte B, Goldman S, Massager N, David P, Wikler D, Lipszyc M, Salmon I, Brotchi J, Levivier M. Combined use of 18F-fluorodeoxyglucose and 11C-methionine in 45 positron emission tomography-guided stereotactic brain biopsies. J Neurosurg. 2004;101:476–83.

    PubMed  CAS  Google Scholar 

  44. Pirotte B, Goldman S, Dewitte O, Massager N, Wikler D, Lefranc F, Taib NOB, Rorive S, David P, Brotchi J, Levivier M. Integrated positron emission tomography and magnetic resonance imaging-guided resection of brain tumors: a report of 103 consecutive procedures. J Neurosurg. 2006;104:238–53.

    PubMed  Google Scholar 

  45. Miwa K, Shinoda J, Yano H, Okumura A, Iwama T, Nakashima T, Sakai N. Discrepancy between lesion distributions on methionine PET and MR images in patients with glioblastoma multiforme: insight from a PET and MR fusion image study. J Neurol Neurosurg Psychiatry. 2004;75:1457–62.

    PubMed  CAS  Google Scholar 

  46. Floeth FW, Sabel M, Ewelt C, Stummer W, Felsberg J, Reifenberger G, Steiger HJ, Stoffels G, Coenen HH, Langen KJ. Comparison of (18)F-FET PET and 5-ALA fluorescence in cerebral gliomas. Eur J Nucl Med Mol Imaging. 2011;38:731–41.

    PubMed  CAS  Google Scholar 

  47. Candiota AP, Majos C, Julia-Sape M, Cabanas M, Acebes JJ, Moreno-Torres A, Griffiths JR, Arus C. Non-invasive grading of astrocytic tumours from the relative contents of myo-inositol and glycine measured by in vivo MRS. JBR-BTR. 2011;94:319–29.

    PubMed  CAS  Google Scholar 

  48. Bluml S, Panigrahy A, Laskov M, Dhall G, Krieger MD, Nelson MD, Finlay JL, Gilles FH. Elevated citrate in pediatric astrocytomas with malignant ­progression. Neuro Oncol. 2011;13:1107–17.

    PubMed  CAS  Google Scholar 

  49. Wijnen JP, Van der Graaf M, Scheenen TW, Klomp DW, de Galan BE, Idema AJ, Heerschap A. In vivo 13C magnetic resonance spectroscopy of a human brain tumor after application of 13C-1-enriched ­glucose. Magn Reson Imaging. 2010;28:690–7.

    PubMed  CAS  Google Scholar 

  50. Day SE, Kettunen MI, Cherukuri MK, Mitchell JB, Lizak MJ, Morris HD, Matsumoto S, Koretsky AP, Brindle KM. Detecting response of rat C6 glioma tumors to radiotherapy using hyperpolarized [1- 13C]pyruvate and 13C magnetic resonance spectroscopic imaging. Magn Reson Med. 2011;65:557–63.

    PubMed  CAS  Google Scholar 

  51. Park I, Bok R, Ozawa T, Phillips JJ, James CD, Vigneron DB, Ronen SM, Nelson SJ. Detection of early response to temozolomide treatment in brain tumors using hyperpolarized 13C MR metabolic imaging. J Magn Reson Imaging. 2011;33:1284–90.

    PubMed  Google Scholar 

  52. Chen W, Cloughesy T, Kamdar N, Satyamurthy N, Bergsneider M, Liau L, Mischel P, Czernin J, Phelps ME, Silverman DHS. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J Nucl Med. 2005;46:945–52.

    PubMed  CAS  Google Scholar 

  53. Price SJ, Fryer TD, Cleij MC, Dean AF, Joseph J, Salvador R, Wang DD, Hutchinson PJ, Clark JC, Burnet NG, Pickard JD, Aigbirhio FI, Gillard JH. Imaging regional variation of cellular proliferation in gliomas using 3’-deoxy-3’-[18F]fluorothymidine positron-emission tomography: an image-guided biopsy study. Clin Radiol. 2009;64:52–63.

    PubMed  CAS  Google Scholar 

  54. Schiepers C, Dahlbom M, Chen W, Cloughesy T, Czernin J, Phelps ME, Huang SC. Kinetics of 3‚Ä›-deoxy-3‚Ä›-18F-fluorothymidine during treatment monitoring of recurrent high-grade glioma. J Nucl Med. 2010;51:720–7.

    PubMed  Google Scholar 

  55. Jacobs AH, Thomas A, Kracht LW, Li H, Dittmar C, Garlip G, Galldiks N, Klein JC, Sobesky J, Hilker R, Vollmar S, Herholz K, Wienhard K, Heiss WD. 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. J Nucl Med. 2005;46:1948–58.

    PubMed  CAS  Google Scholar 

  56. Nafe R, Herminghaus S, Raab P, Wagner S, Pilatus U, Schneider B, Schlote W, Zanella F, Lanfermann H. Preoperative proton-MR spectroscopy of gliomas—correlation with quantitative nuclear morphology in surgical specimen. J Neurooncol. 2003;63:233–45.

    PubMed  Google Scholar 

  57. McKnight TR, Lamborn KR, Love TD, Berger MS, Chang S, Dillon WP, Bollen A, Nelson SJ. Correlation of magnetic resonance spectroscopic and growth characteristics within Grades II and III gliomas. J Neurosurg. 2007;106:660–6.

    PubMed  CAS  Google Scholar 

  58. Lam WW, Ng DC, Wong WY, Ong SC, Yu SW, See SJ. Promising role of [18F] fluorocholine PET/CT vs [18F] fluorodeoxyglucose PET/CT in primary brain tumors-early experience. Clin Neurol Neurosurg. 2011;113:156–61.

    PubMed  Google Scholar 

  59. Remy C, Fouilhe N, Barba I, Sam-Lai E, Lahrech H, Cucurella MG, Izquierdo M, Moreno A, Ziegler A, Massarelli R, Decorps M, Arus C. Evidence that mobile lipids detected in rat brain glioma by 1H nuclear magnetic resonance correspond to lipid droplets. Cancer Res. 1997;57:407–14.

    PubMed  CAS  Google Scholar 

  60. Price SJ, Tozer DJ, Gillard JH. Methodology of diffusion-weighted, diffusion tensor and magnetisation transfer imaging. Br J Radiol. 2011;84:S121–6.

    PubMed  Google Scholar 

  61. Latour LL, Svoboda K, Mitra PP, Sotak CH. Time-dependent diffusion of water in a biological model system. Proc Natl Acad Sci U S A. 1994;91:1229–33.

    PubMed  CAS  Google Scholar 

  62. Guo AC, Cummings TJ, Dash RC, Provenzale JM. Lymphomas and high-grade astrocytomas: comparison of water diffusibility and histologic characteristics. Radiology. 2002;224:177–83.

    PubMed  Google Scholar 

  63. Gauvain KM, McKinstry RC, Mukherjee P, Perry A, Neil JJ, Kaufman BA, Hayashi RJ. Evaluating pediatric brain tumor cellularity with diffusion-tensor imaging. AJR Am J Roentgenol. 2001;177:449–54.

    PubMed  CAS  Google Scholar 

  64. Sugahara T, Korogi Y, Kochi M, Ikushima I, Shigematu Y, Hirai T, Okuda T, Liang L, Ge Y, Komohara Y, Ushio Y, Takahashi M. Usefulness of ­diffusion-weighted MRI with echo-planar technique in the evaluation of cellularity in gliomas. J Magn Reson Imaging. 1999;9:53–60.

    PubMed  CAS  Google Scholar 

  65. Bastin ME, Carpenter TK, Armitage PA, Sinha S, Wardlaw JM, Whittle IR. Effects of dexamethasone on cerebral perfusion and water diffusion in patients with high-grade glioma. AJNR Am J Neuroradiol. 2006;27:402–8.

    PubMed  CAS  Google Scholar 

  66. Lam WW, Poon WS, Metreweli C. Diffusion MR imaging in glioma: does It have Any role in the pre-operation determination of grading of glioma? Clin Radiol. 2002;57:219–25.

    PubMed  CAS  Google Scholar 

  67. Chenevert TL, McKeever PE, Ross BD. Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging. Clin Cancer Res. 1997;3:1457–66.

    PubMed  CAS  Google Scholar 

  68. Mardor Y, Roth Y, Lidar Z, Jonas T, Pfeffer R, Maier SE, Faibel M, Nass D, Hadani M, Orenstein A, Cohen JS, Ram Z. Monitoring response to convection-enhanced taxol delivery in brain tumor patients using diffusion-weighted magnetic resonance imaging. Cancer Res. 2001;61:4971–3.

    PubMed  CAS  Google Scholar 

  69. Chenevert TL, Stegman LD, Taylor JM, Robertson PL, Greenberg HS, Rehemtulla A, Ross BD. Diffusion magnetic resonance imaging: an early surrogate marker of therapeutic efficacy in brain tumors. J Natl Cancer Inst. 2000;92:2029–36.

    PubMed  CAS  Google Scholar 

  70. Sadeghi N, Camby I, Goldman S, Gabius HJ, Baleriaux D, Salmon I, Decaesteckere C, Kiss R, Metens T. Effect of hydrophilic components of the extracellular matrix on quantifiable diffusion-weighted imaging of human gliomas: preliminary results of correlating apparent diffusion coefficient values and hyaluronan expression level. AJR Am J Roentgenol. 2003;181:235–41.

    PubMed  Google Scholar 

  71. Tozer DJ, Rees JH, Benton CE, Waldman AD, Jager HR, Tofts PS. Quantitative magnetisation transfer imaging in glioma: preliminary results. NMR Biomed. 2011;24:492–8.

    PubMed  Google Scholar 

  72. Waldman A, Rees JH, Brock CS, Robson MD, Gatehouse PD, Bydder GM. MRI of the brain with ultra-short echo-time pulse sequences. Neuroradiology. 2003;45:887–92.

    PubMed  CAS  Google Scholar 

  73. Sugahara T, Korogi Y, Kochi M, Ikushima I, Hirai T, Okuda T, Shigematsu Y, Liang L, Ge Y, Ushio Y, Takahashi M. Correlation of MR imaging-determined cerebral blood volume maps with histologic and angiographic determination of vascularity of gliomas. AJR Am J Roentgenol. 1998;171:1479–86.

    PubMed  CAS  Google Scholar 

  74. Maia AC, Malheiros SM, da Rocha AJ, da Silva CJ, Gabbai AA, Ferraz FA, Stavale JN. MR cerebral blood volume maps correlated with vascular endothelial growth factor expression and tumor grade in nonenhancing gliomas. AJNR Am J Neuroradiol. 2005;26:777–83.

    PubMed  Google Scholar 

  75. Law M, Yang S, Babb JS, Knopp EA, Golfinos JG, Zagzag D, Johnson G. Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol. 2004;25:746–55.

    PubMed  Google Scholar 

  76. Law M, Yang S, Wang H, Babb JS, Johnson G, Cha S, Knopp EA, Zagzag D. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol. 2003;24:1989–98.

    PubMed  Google Scholar 

  77. Patankar TF, Haroon HA, Mills SJ, Baleriaux D, Buckley DL, Parker GJM, Jackson A. Is volume transfer coefficient (Ktrans) related to histologic grade in human gliomas? AJNR Am J Neuroradiol. 2005;26:2455–65.

    PubMed  Google Scholar 

  78. Law M, Oh S, Babb JS, Wang E, Inglese M, Zagzag D, Knopp EA, Johnson G. Low-grade gliomas: dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging—prediction of patient clinical response. Radiology. 2006;238:658–67.

    PubMed  Google Scholar 

  79. Danchaivijitr N, Waldman AD, Tozer DJ, Benton CE, Brasil Caseiras G, Tofts PS, Rees JH, Jager HR. Low-grade gliomas: do changes in rCBV measurements at longitudinal perfusion-weighted MR imaging predict malignant transformation? Radiology. 2008;247:170–8.

    PubMed  Google Scholar 

  80. Cha S, Tihan T, Crawford F, Fischbein NJ, Chang S, Bollen A, Nelson SJ, Prados M, Berger MS, Dillon WP. Differentiation of low-grade oligodendrogliomas from Low-grade astrocytomas by using quantitative blood-volume measurements derived from dynamic susceptibility contrast-enhanced MR imaging. AJNR Am J Neuroradiol. 2005;26:266–73.

    PubMed  Google Scholar 

  81. Lev MH, Ozsunar Y, Henson JW, Rasheed AA, Barest GD, Harsh GR, Fitzek MM, Chiocca EA, Rabinov JD, Csavoy AN, Rosen BR, Hochberg FH, Schaefer PW, Gonzalez RG. Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas. AJNR Am J Neuroradiol. 2004;25:214–21.

    PubMed  Google Scholar 

  82. Weber MA, Zoubaa S, Schlieter M, Juttler E, Huttner HB, Geletneky K, Ittrich C, Lichy MP, Kroll A, Debus J, Giesel FL, Hartmann M, Essig M. Diagnostic performance of spectroscopic and perfusion MRI for distinction of brain tumors. Neurology. 2006;66:1899–906.

    PubMed  CAS  Google Scholar 

  83. Mangla R, Singh G, Ziegelitz D, Milano MT, Korones DN, Zhong J, Ekholm SE. Changes in relative cerebral blood volume 1 month after radiation-temozolomide therapy Can help predict overall survival in patients with glioblastoma1. Radiology. 2010;256:575–84.

    PubMed  Google Scholar 

  84. Sorensen AG, Batchelor TT, Zhang WT, Chen PJ, Yeo P, Wang M, Jennings D, Wen PY, Lahdenranta J, Ancukiewicz M, di Tomaso E, Duda DG, Jain RK. A “vascular normalization index” as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res. 2009;69:5296–300.

    PubMed  CAS  Google Scholar 

  85. Battle MR, Goggi JL, Allen L, Barnett J, Morrison MS. Monitoring tumor response to antiangiogenic sunitinib therapy with 18F-fluciclatide, an 18F-labeled αVβ3-integrin and αVβ5-integrin imaging agent. J Nucl Med. 2011;52:424–30.

    PubMed  CAS  Google Scholar 

  86. Gray LH, Conger AD, Ebert M, Hornsey S, Scott OCA. The concentration of oxygen dissolved in tissues at the time of irradiation as a factor in ­radiotherapy. Br J Radiol. 1953;26:638–48.

    PubMed  CAS  Google Scholar 

  87. Hsu YY, Chang CN, Jung SM, Lim KE, Huang JC, Fang SY, Liu HL. Blood oxygenation level-dependent MRI of cerebral gliomas during breath holding. J Magn Reson Imaging. 2004;19:160–7.

    PubMed  Google Scholar 

  88. Valk PE, Mathis CA, Prados MD, Gilbert JC, Budinger TF. Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole. J Nucl Med. 1992;33:2133–7.

    PubMed  CAS  Google Scholar 

  89. Cher LM, Murone C, Lawrentschuk N, Ramdave S, Papenfuss A, Hannah A, O’Keefe GJ, Sachinidis JI, Berlangieri SU, Fabinyi G, Scott AM. Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies. J Nucl Med. 2006;47:410–8.

    PubMed  CAS  Google Scholar 

  90. Spence AM, Muzi M, Swanson KR, O’Sullivan F, Rockhill JK, Rajendran JG, Adamsen TCH, Link JM, Swanson PE, Yagle KJ, Rostomily RC, Silbergeld DL, Krohn KA. Regional hypoxia in glioblastoma multiforme quantified with [18F]fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival. Clin Cancer Res. 2008;14:2623–30.

    PubMed  CAS  Google Scholar 

  91. Croteau D, Scarpace L, Hearshen D, Gutierrez J, Fisher JL, Rock JP, Mikkelsen T. Correlation between magnetic resonance spectroscopy imaging and image- guided biopsies: semiquantitative and qualitative histopathological analyses of patients with untreated glioma. Neurosurgery. 2001;49:823–9.

    PubMed  CAS  Google Scholar 

  92. Murphy M, Loosemore A, Clifton AG, Howe FA, Tate AR, Cudlip SA, Wilkins PR, Griffiths JR, Bell BA. The contribution of proton magnetic resonance spectroscopy (1HMRS) to clinical brain tumour diagnosis. Br J Neurosurg. 2002;16:329–34.

    PubMed  CAS  Google Scholar 

  93. Lee SW, Fraass BA, Marsh LH, Herbort K, Gebarski SS, Martel MK, Radany EH, Lichter AS, Sandler HM. Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: a quantitative dosimetric study. Int J Radiat Oncol Biol Phys. 1999;43:79–88.

    PubMed  CAS  Google Scholar 

  94. Oppitz U, Maessen D, Zunterer H, Richter S, Flentje M. 3D-recurrence-patterns of glioblastomas after CT-planned postoperative irradiation. Radiother Oncol. 1999;53:53–7.

    PubMed  CAS  Google Scholar 

  95. Jena R, Price SJ, Baker C, Jefferies SJ, Pickard JD, Gillard JH, Burnet NG. Diffusion tensor imaging: possible implications for radiotherapy treatment planning of patients with high-grade glioma. Clin Oncol. 2005;17:581–90.

    CAS  Google Scholar 

  96. Stupp R, Hegi ME, Neyns B, Goldbrunner R, Schlegel U, Clement PMJ, Grabenbauer GG, Ochsenbein AF, Simon M, Dietrich PY, Pietsch T, Hicking C, Tonn JC, Diserens AC, Pica A, Hermisson M, Krueger S, Picard M, Weller M. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010;28:2712–8.

    PubMed  CAS  Google Scholar 

  97. Papadakis NG, Xing D, Houston GC, Smith JM, Smith MI, James MF, Parsons AA, Huang CL, Hall LD, Carpenter TA. A study of rotationally invariant and symmetric indices of diffusion anisotropy. Magn Reson Imaging. 1999;17:881–92.

    PubMed  CAS  Google Scholar 

  98. Price S, Burnet N, Donovan T, Green H, Pena A, Antoun N, Pickard J, Carpenter T, Gillard J. Diffusion tensor imaging of brain tumours at 3T: a potential tool for assessing white matter tract invasion? Clin Radiol. 2003;58:455–62.

    PubMed  CAS  Google Scholar 

  99. Witwer BP, Moftakhar R, Hasan KM, Deshmukh P, Haughton V, Field A, Arfanakis K, Noyes J, Moritz CH, Meyerand ME, Rowley HA, Alexander AL, Badie B. Diffusion-tensor imaging of white matter tracts in patients with cerebral neoplasm. J Neurosurg. 2002;97:568–75.

    PubMed  Google Scholar 

  100. Price S, Pena A, Burnet N, Jena R, Green H, Carpenter T, Pickard J, Gillard J. Tissue signature characterisation of diffusion tensor abnormalities in cerebral gliomas. Eur Radiol. 2004;14:1909–17.

    PubMed  Google Scholar 

  101. Price S, Jena R, Burnet N, Carpenter T, Pickard J, Gillard J. Predicting patterns of glioma recurrence using diffusion tensor imaging. Eur Radiol. 2007;17:1675–84.

    PubMed  Google Scholar 

  102. Price SJ, Jena R, Burnet NG, Hutchinson PJ, Dean AF, Pena A, Pickard JD, Carpenter TA, Gillard JH. Improved delineation of glioma margins and regions of infiltration with the use of diffusion tensor imaging: an image-guided biopsy study. AJNR Am J Neuroradiol. 2006;27:1969–74.

    PubMed  CAS  Google Scholar 

  103. Goebell E, Fiehler J, Ding XQ, Paustenbach S, Nietz S, Heese O, Kucinski T, Hagel C, Westphal M, Zeumer H. Disarrangement of fiber tracts and decline of neuronal density correlate in glioma patients—a combined diffusion tensor imaging and 1H-MR spectroscopy study. AJNR Am J Neuroradiol. 2006;27:1426–31.

    PubMed  CAS  Google Scholar 

  104. Pirzkall A, Li X, Oh J, Chang S, Berger MS, Larson DA, Verhey LJ, Dillon WP, Nelson SJ. 3D MRSI for resected high-grade gliomas before RT: tumor extent according to metabolic activity in relation to MRI. Int J Radiat Oncol Biol Phys. 2004;59:126–37.

    PubMed  Google Scholar 

  105. Stadlbauer A, Nimsky C, Gruber S, Moser E, Hammen T, Engelhorn T, Buchfelder M, Ganslandt O. Changes in fiber integrity, diffusivity, and metabolism of the pyramidal tract adjacent to gliomas: a quantitative diffusion tensor fiber tracking and MR spectroscopic imaging study. AJNR Am J Neuroradiol. 2007;28:462–9.

    PubMed  CAS  Google Scholar 

  106. Kimura T, Ohkubo M, Igarashi H, Kwee IL, Nakada T. Increase in glutamate as a sensitive indicator of extracellular matrix integrity in peritumoral edema: a 3.0-tesla proton magnetic resonance spectroscopy study. J Neurosurg. 2007;106:609–13.

    PubMed  CAS  Google Scholar 

  107. Di Costanzo A, Scarabino T, Trojsi F, Popolizio T, Catapano D, Giannatempo GM, Bonavita S, Portaluri M, Tosetti M, d’Angelo VA, Salvolini U, Tedeschi G. Proton MR spectroscopy of cerebral gliomas at 3 T: spatial heterogeneity, and tumour grade and extent. Eur Radiol. 2008;18:1727–35.

    PubMed  Google Scholar 

  108. Zhang K, Li C, Liu Y, Li L, Ma X, Meng X, Feng D. Evaluation of invasiveness of astrocytoma using 1H-magnetic resonance spectroscopy: correlation with expression of matrix metalloproteinase-2. Neuroradiology. 2007;49:913–9.

    PubMed  Google Scholar 

  109. Mosskin M, Bergstrom M, Collins VP, Ehrin E, Eriksson L, von Holst H, Noren G. Positron emission tomography with 11C-methionine of intracranial tumours compared with histology of multiple biopsies. Acta Radiol. 1986;369:157–60.

    CAS  Google Scholar 

  110. Mosskin M, Ericson K, Hindmarsh T, von Holst H, Collins VP, Bergstrom M, Eriksson L, Johnstrom P. Positron emission tomography compared with magnetic resonance imaging and computed tomography in supratentorial gliomas using multiple stereotactic biopsies as reference. Acta Radiol. 1989;30:225–32.

    PubMed  CAS  Google Scholar 

  111. Kracht LW, Miletic H, Busch S, Jacobs AH, Voges J, Hoevels M, Klein JC, Herholz K, Heiss WD. Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology. Clin Cancer Res. 2004;10:7163–70.

    PubMed  CAS  Google Scholar 

  112. Stadlbauer A, Prante O, Nimsky C, Salomonowitz E, Buchfelder M, Kuwert T, Linke R, Ganslandt O. Metabolic imaging of cerebral gliomas: spatial correlation of changes in O-(2–18F-fluoroethyl)-L-tyrosine PET and proton magnetic resonance spectroscopic imaging. J Nucl Med. 2008;49:721–9.

    PubMed  CAS  Google Scholar 

  113. Stadlbauer A, Pölking E, Prante O, Nimsky C, Buchfelder M, Kuwert T, Linke R, Doelken M, Ganslandt O. Detection of tumour invasion into the pyramidal tract in glioma patients with sensorimotor deficits by correlation of 18 F-fluoroethyl-L-tyrosine PET and magnetic resonance diffusion tensor ­imaging. Acta Neurochir (Wien). 2009;151:1061–9.

    Google Scholar 

  114. Henry RG, Vigneron DB, Fischbein NJ, Grant PE, Day MR, Noworolski SM, Star-Lack JM, Wald LL, Dillon WP, Chang SM, Nelson SJ. Comparison of relative cerebral blood volume and proton spectroscopy in patients with treated gliomas. AJNR Am J Neuroradiol. 2000;21:357–66.

    PubMed  CAS  Google Scholar 

  115. Blasel S, Franz K, Mittelbronn M, Morawe G, Jurcoane A, Pellikan S, Zanella F, Hattingen E. The striate sign: peritumoural perfusion pattern of infiltrative primary and recurrent gliomas. Neurosurg Rev. 2010;33:193–203. discussion 203–194.

    PubMed  Google Scholar 

  116. Blasel S, Franz K, Ackermann H, Weidauer S, Zanella F, Hattingen E. Stripe-like increase of rCBV beyond the visible border of glioblastomas: site of tumor infiltration growing after neurosurgery. J Neurooncol. 2011;103:575–84.

    PubMed  Google Scholar 

  117. Price SJ, Green HA, Dean AF, Joseph J, Hutchinson PJ, Gillard JH. Correlation of MR relative cerebral blood volume measurements with cellular density and proliferation in high-grade gliomas: an image-guided biopsy study. AJNR Am J Neuroradiol. 2011;32:501–6.

    PubMed  CAS  Google Scholar 

  118. Lehmann P, Vallee JN, Saliou G, Monet P, Bruniau A, Fichten A, De MG. Dynamic contrast-enhanced T2*-weighted MR imaging: a peritumoral brain oedema study. J Neuroradiol. 2009;36:88–92.

    PubMed  CAS  Google Scholar 

  119. Bennewitz MF, Tang KS, Markakis EA, Shapiro EM: Specific Chemotaxis of Magnetically Labeled Mesenchymal Stem Cells: Implications for MRI of Glioma. Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging, 2012

    Google Scholar 

  120. Jenkinson MD, du Plessis DG, Smith TS, Joyce KA, Warnke PC, Walker C. Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features. Brain. 2006;129:1884–91.

    PubMed  Google Scholar 

  121. Jenkinson MD, Smith TS, Joyce KA, Fildes D, Broome J, du Plessis DG, Haylock B, Husband DJ, Warnke PC, Walker C. Cerebral blood volume, genotype and chemosensitivity in oligodendroglial tumours. Neuroradiology. 2006;48:703–13.

    PubMed  Google Scholar 

  122. Law M, Brodsky JE, Babb J, Rosenblum M, Miller DC, Zagzag D, Gruber ML, Johnson G. High cerebral blood volume in human gliomas predicts deletion of chromosome 1p: Preliminary results of molecular studies in gliomas with elevated perfusion. J Magn Reson Imaging. 2007;25:1113–9.

    PubMed  Google Scholar 

  123. Kapoor G, Gocke T, Chawla S, Whitmore R, Nabavizadeh A, Krejza J, Lopinto J, Plaum J, Maloney-Wilensky E, Poptani H, Melhem E, Judy K, O’Rourke D. Magnetic resonance perfusion-weighted imaging defines angiogenic subtypes of oligodendroglioma according to 1p19q and EGFR status. J Neurooncol. 2009;92:373–86.

    PubMed  Google Scholar 

  124. Jenkinson MD, Smith TS, Brodbelt AR, Joyce KA, Warnke PC, Walker C. Apparent diffusion coefficients in oligodendroglial tumors characterized by genotype. J Magn Reson Imaging. 2007;26:1405–12.

    PubMed  Google Scholar 

  125. Jenkinson MD, Smith TS, Joyce K, Fildes D, du Plessis DG, Warnke PC, Walker C. MRS of oligodendroglial tumors: correlation with histopathology and genetic subtypes. Neurology. 2005;64:2085–9.

    PubMed  CAS  Google Scholar 

  126. Stockhammer F, Thomale UW, Plotkin M, Hartmann C, Von DA. Association between fluorine-18-labeled fluorodeoxyglucose uptake and 1p and 19q loss of heterozygosity in World Health Organization Grade II gliomas. J Neurosurg. 2007;106:633–7.

    PubMed  CAS  Google Scholar 

  127. Drabycz S, Roldan G, de Robles P, Adler D, McIntyre JB, Magliocco AM, Cairncross JG, Mitchell JR. An analysis of image texture, tumor location, and MGMT promoter methylation in glioblastoma using magnetic resonance imaging. Neuroimage. 2010;49:1398–405.

    PubMed  CAS  Google Scholar 

  128. Moon WJ, Choi J, Roh H, Lim S, Koh YC. Imaging parameters of high grade gliomas in relation to the MGMT promoter methylation status: the CT, diffusion tensor imaging, and perfusion MR imaging. Neuroradiology. 2012;54(6):555–63.

    PubMed  Google Scholar 

  129. Pope WB, Prins RM, Albert Thomas M, Nagarajan R, Yen KE, Bittinger MA, Salamon N, Chou AP, Yong WH, Soto H, Wilson N, Driggers E, Jang HG, Su SM, Schenkein DP, Lai A, Cloughesy TF, Kornblum HI, Wu H, Fantin VR, Liau LM. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. J Neurooncol. 2012;107:197–205.

    PubMed  CAS  Google Scholar 

  130. Jalbert L, Elkhaled A, Phillips J, Yoshihara H, Srinivasan R, Bourne G, Chang S, Cha S, Nelson S. Presence of 2-Hydroxyglutarate in IDH-1 mutated low-grade glioma using ex vivo proton HR-MAS. Proc Int Soc Mag Reson Med. 2011;19:183.

    Google Scholar 

  131. Aghi M, Gaviani P, Henson JW, Batchelor TT, Louis DN, Barker II FG. Magnetic resonance imaging characteristics predict epidermal growth factor receptor amplification status in glioblastoma. Clin Cancer Res. 2005;11:8600–5.

    PubMed  CAS  Google Scholar 

  132. Abourbeh G, Dissoki S, Jacobson O, Litchi A, Ben Daniel R, Laki D, Levitzki A, Mishani E. Evaluation of radiolabeled ML04, a putative irreversible inhibitor of epidermal growth factor receptor, as a bioprobe for PET imaging of EGFR-overexpressing tumors. Nucl Med Biol. 2007;34:55–70.

    PubMed  CAS  Google Scholar 

  133. Mishani E, Abourbeh G, Rozen Y, Jacobson O, Laky D, Ben David I, Levitzki A, Shaul M. Novel carbon-11 labeled 4-dimethylamino-but-2-enoic acid [4-(phenylamino)-quinazoline-6-yl]-amides: potential PET bioprobes for molecular imaging of EGFR-positive tumors. Nucl Med Biol. 2004;31:469–76.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Neurosurgery Division and Wolfson Brain Imaging Centre, Department of Clinical Neurosciences, University of Cambridge, 167, Addenbrooke’s Hospital, Hill Road, Cambridge, CB2 0QQ, UK

    Stephen J. Price BSc., MBBS, PhD, FRCS

  2. Department of Imaging, Imperial College, London, UK

    Adam D. Waldman Ph.D., FRCP, FRCR

Authors
  1. Stephen J. Price BSc., MBBS, PhD, FRCS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Adam D. Waldman Ph.D., FRCP, FRCR
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stephen J. Price BSc., MBBS, PhD, FRCS .

Editor information

Editors and Affiliations

  1. , Department of Clinical Neurosciences, University of Cambridge, Hills Road, Cambridge, CB2 0QQ, United Kingdom

    Colin Watts

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag London

About this chapter

Cite this chapter

Price, S.J., Waldman, A.D. (2013). Advances in Imaging Brain Cancer. In: Watts, C. (eds) Emerging Concepts in Neuro-Oncology. Springer, London. https://doi.org/10.1007/978-0-85729-458-6_8

Download citation

  • DOI: https://doi.org/10.1007/978-0-85729-458-6_8

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-0-85729-457-9

  • Online ISBN: 978-0-85729-458-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation